Bleomycin Hydrolase, Recombinant, Human (BH, BLMH, BMH, BLM Hydrolase)

Bleomycin Hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the antitumor agent bleomycin and inactivate it. It has a papain­like catalytic triad (Cys­His­Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up­regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300kD. In addition to its aminopeptidase activity, it has homocysteine­ thiolactonase activity. The normal physiological function of BLMH is not clear. BLMH inactivates bleomycin, a glycopeptide anticancer agent, by deaminating it. BLMH has been suggested to play a role in the generation of MHC class I­presented peptides. Diminished BLMH activity may contribute to the pathology of Alzheimer's disease (AD) (5­6). It is inhibited by cysteine protease inhibitors such as N­ethylmaleimide, iodoacetamide, para­hydroxymercuribenzoate, and E­64. Source: E.coli-derived, Ser2-Glu455, with an N-terminal Met and 6-His tag. SDS-PAGE: 45-50kD, reducing conditions, Activity: Measured by its ability to hydrolyze Met-AMC. Specific Activity: >500pmoles/min/ug. Endotoxin Level: <1EU/1ug (LAL) , Storage and Stability:, For long-term storage, aliquot to avoid repeated freezing and thawing and freeze at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months.